Corcept Therapeutics Inc. (CORT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Corcept Therapeutics’s revenue went from $81M in fiscal 2016 to $761M in fiscal 2025, growth of about 28.2% a year.
Net income in fiscal 2025 was $100M, a net margin of 13.1%; the best year in this period was 2024 with $141M.
Over the twelve months to September 30, 2026, revenue was $964M and net income $159M.
Free cash flow was $142M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 3% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $964M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M |
| Gross profit | $950M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M |
| Operating income | $111M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M |
| Net income | $159M | $100M | $141M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M |
| EPS (diluted) | $1.33 | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| R&D | $242M | $255M | $247M | $184M | $131M | $114M | $115M | $89M | $75M | $40M | $24M |
| Revenue growth | — | +12.8% | +39.9% | +20.0% | +9.8% | +3.4% | +15.5% | +22.0% | +57.8% | +95.8% | +61.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $198M | $142M | $198M | $127M | $120M | $168M | $152M | $136M | $116M | $61M | $18M |
| Capital spending | -$3M | -$211000 | -$2M | -$139000 | -$413000 | -$469000 | -$1M | -$1M | -$298000 | -$419000 | -$194000 |
| Free cash flow | $195M | $142M | $196M | $127M | $120M | $167M | $151M | $135M | $115M | $61M | $18M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $6M | $173M | $16M | $0 | $0 | — | $10M | $31M | $24M | $0 | $0 |
| Stock-based pay | $103M | $84M | $61M | $49M | $42M | $43M | $34M | $29M | $24M | $13M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $372M | $383M | $368M | $432M | $224M | $441M | $276M | $207M | $89M | $52M |
| Debt | — | $6M | $7M | $151000 | $1M | $526000 | $3M | $3M | — | $0 | $15M |
| Equity | — | $648M | $680M | $507M | $502M | $376M | $523M | $371M | $276M | $191M | $41M |
| Total assets | — | $837M | $841M | $622M | $583M | $424M | $572M | $412M | $312M | $221M | $69M |
| Shares (diluted) | 123M | 120M | 113M | 112M | 116M | 126M | 124M | 123M | 127M | 125M | 116M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 98.5% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating margin | 11.5% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net margin | 16.5% | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| FCF margin | 20.2% | 18.6% | 29.0% | 26.2% | 29.8% | 45.8% | 42.6% | 44.1% | 45.9% | 38.0% | 22.4% |
| ROIC | — | 5.4% | 17.4% | 18.0% | 19.6% | 29.8% | 19.6% | 24.1% | 26.6% | 21.9% | 18.2% |
| ROE | — | 15.4% | 20.8% | 20.9% | 20.2% | 29.9% | 20.3% | 25.4% | 27.3% | 67.6% | 19.7% |
Frequently asked questions
What is Corcept Therapeutics’s annual revenue?
$761M in fiscal 2025 and $964M over the twelve months to September 30, 2026.
How much profit does Corcept Therapeutics make?
Net income was $100M in fiscal 2025 (net margin 13.1%).
Is Corcept Therapeutics’s revenue growing?
Yes: revenue rose 12.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.